XERIS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Accounts Payable
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase (Decrease) in Accounts Payable of $4.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $286.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $4.25M, a 4.63% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.70M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $2.00M, a 20.75% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$69.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$9.61M, a 238.14% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for fiscal 2023 was $6.96M.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in accounts payable for fiscal 2022 was -$4.32M, a 178.13% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.54M 10-Q · filed 2026-08-06 | $2.84M derived: sum of 3 quarters · filed 2026-08-06 | $4.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.25M 10-Q · filed 2026-05-07 | $2.55M derived: sum of 2 quarters · filed 2026-05-07 | $4.55M derived: sum of 3 quarters · filed 2026-05-07 | $119.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $298.00K derived: sum of 2 quarters · filed 2026-03-02 | -$4.13M derived: sum of 3 quarters · filed 2026-08-06 | -$69.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.43M derived: sum of 2 quarters · filed 2026-08-06 | $1.63M 10-Q · filed 2025-11-06 | -$3.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$4.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$367.00K 10-Q · filed 2026-08-06 | -$5.57M derived: sum of 3 quarters · filed 2026-08-06 | -$3.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.06M 10-Q · filed 2026-05-07 | -$1.14M derived: sum of 2 quarters · filed 2026-05-07 | $512.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$3.55M derived: sum of 2 quarters · filed 2026-03-02 | -$5.14M derived: sum of 3 quarters · filed 2026-03-02 | -$9.61M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $61.00K derived: sum of 2 quarters · filed 2025-11-06 | -$4.41M 10-Q · filed 2025-11-06 | -$4.76M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$6.06M 10-Q · filed 2025-08-07 | -$6.42M derived: sum of 3 quarters · filed 2026-03-02 | -$6.12M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$4.47M 10-Q · filed 2025-05-08 | -$4.82M derived: sum of 2 quarters · filed 2026-03-02 | -$4.53M derived: sum of 3 quarters · filed 2026-03-02 | -$4.45M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$353.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$56.00K derived: sum of 2 quarters · filed 2026-03-02 | $24.00K derived: sum of 3 quarters · filed 2026-03-02 | $6.96M 10-K · filed 2026-03-02 |
| 2023-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $377.00K derived: sum of 2 quarters · filed 2024-11-08 | $7.31M 10-Q · filed 2024-11-08 | $8.00M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $7.01M 10-Q · filed 2024-08-08 | $7.71M derived: sum of 3 quarters · filed 2025-03-06 | $4.99M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $6.93M 10-Q · filed 2024-05-09 | $7.63M derived: sum of 2 quarters · filed 2025-03-06 | $4.91M derived: sum of 3 quarters · filed 2025-03-06 | $449.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $690.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$2.02M derived: sum of 2 quarters · filed 2025-03-06 | -$6.49M derived: sum of 3 quarters · filed 2025-03-06 | -$4.32M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$7.18M derived: sum of 2 quarters · filed 2023-11-09 | -$5.01M 10-Q · filed 2023-11-09 | -$654.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.29M 10-Q · filed 2023-08-08 | $2.06M derived: sum of 3 quarters · filed 2024-03-06 | $1.17M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $2.17M 10-Q · filed 2023-05-09 | $6.52M derived: sum of 2 quarters · filed 2024-03-06 | $5.63M derived: sum of 3 quarters · filed 2024-03-06 | $6.04M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $3.46M derived: sum of 2 quarters · filed 2024-03-06 | $3.88M derived: sum of 3 quarters · filed 2024-03-06 | $5.53M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$895.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$478.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.17M 10-Q · filed 2022-11-09 | -$404.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.07M 10-Q · filed 2022-08-10 | $491.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $1.65M 10-Q · filed 2022-05-11 | $74.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$2.49M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | -$909.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |